Promoters of Marksans Pharma Limited have declared that they have not created any encumbrance on their shareholdings in the company. The disclosure was submitted to the stock exchanges in compliance with regulatory requirements.

Regulatory Disclosure

The declaration was made under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The promoters confirmed that they have not made any encumbrance, directly or indirectly, of the shares held by them in Marksans Pharma Limited.

Submission Details

The communication was addressed to BSE Limited and the National Stock Exchange of India Limited on April 02, 2026. The document was signed by Mark Saldanha and Sandra Saldanha, the undersigned promoters of the company. A copy of the declaration was also marked to the Audit Committee of Directors.

Marksans Pharma Limited has scheduled a Q4FY26 earnings conference call for analysts and investors on Wednesday, May 27, 2026, at 04:30 PM IST. The announcement was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call will cover the audited financial results — both Standalone and Consolidated — for the quarter and year ended March 31, 2026.

Conference Call Details

The earnings call will feature senior members of Marksans Pharma's management team and will be facilitated by DAM Capital Advisors Ltd. The following key details summarise the event:

Management Speakers

The following members of Marksans Pharma's leadership will address the call:

• Mr. Mark Saldanha – Founder, Chairman and Managing Director
• Mr. Jitendra Sharma – Chief Financial Officer

Dial-In Information

Participants can join the call using the following access numbers. The company advises dialling in at least 5–10 minutes prior to the scheduled start time.

Universal Access (all networks and countries):

• +91 22 6280 1384
• +91 22 7115 8285

International Dial-In Numbers:

For further information, participants may contact Nitin Agarwal or Payal Shah at DAM Capital Advisors Limited via phone at +91 22 4202 2568 / 2638 or by email at nitin.a@damcapital.in / payal@damcapital.in .

Post-Call Resources

Following the conference call, the presentation, audio recording, and transcript will be hosted on the company's official website at https://www.marksanspharma.com/earnings-call-transcripts.html . The intimation letter was signed by Harshavardhan Panigrahi, Company Secretary, on May 19, 2026.